May-Thurner SyndromeMTSNCT05409781
Prevalence of May-Thurner Syndrome in 1st-degree Relatives of Symptomatic Patients
An observational study of May-Thurner Syndrome, run by University Hospital of Limerick.
Trial summary
The aim is to assess the prevalence of May-Thurner syndrome in 1st-degree relatives of previously identified symptomatic patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- May-Thurner Syndrome
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 15 Sep 2025to 15 Jan 2026
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The pathogenesis of MTS is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. To our knowledge, no studies have previously assessed the prevalence of MTS in relatives of those with the condition.
Who may be able to join
- Informed consent, first degree relative with symptomatic May-Thurner syndrome
Who cannot join
- Those who not give informed consent to be contacted or to be scanned.
About this study
The aim is to assess the prevalence of May-Thurner syndrome in 1st-degree relatives of previously identified symptomatic patients.
Read the detailed description
May-Thurner syndrome (MTS) is a condition characterised by compression of the left common iliac vein by the right common iliac artery and the anterior spine of the 5th lumbar vertebrae. Previously thought to be a rare condition, the prevalence of MTS is thought to be underreported. MTS can lead to significant morbidity in the form of chronic venous insufficiency, venous ulceration, lower limb swelling, venous claudication, deep-vein thrombosis, varicose veins, pelvic congestion syndrome, chronic pelvic pain and chronic post-thrombotic syndrome. It is a known risk factor for development of venous incompetence and varicose veins in adolescents and young adults. Furthermore, it is known to be an a causative factor in the development of "unprovoked" DVT in younger patients, however data on the risk of development of DVT in MTS patients has to date, been unavailable.
The pathogenesis of MTS is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. To date, no studies have previously assessed the prevalence of MTS in relatives of those with the condition.
- Conditions
- May-Thurner Syndrome
- Being tested
- No Intervention
- Medical subject headings
- May-Thurner Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No InterventionOther
No Intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence Assessment
To assess the prevalence of May-Thurner syndrome amongst 1st-degree relatives of symptomatic individuals referred to the Vascular Department, University Hospital Limerick using duplex ultrasound imaging
Measured: 1 year
Secondary outcomes (1)
Venous Competence Assessment
To assess concomitant venous incompetence of the lower limb
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2022
- Study start15 Sep 2025 (estimated)
- Primary completion15 Dec 2025 (estimated)
- Study completion15 Jan 2026 (estimated)
Why it stopped: Decided amongst research group that this project is not feasible
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for May-Thurner SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- University Hospital of Limerick
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fiona Leahy, University Hospital of Limerick
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05409781
- Sponsor's protocol ID
- DVS002
- Acronym
- MTS
- Status last verified
- Sep 2025
- First submitted
- 3 Jun 2022
- Last updated
- 18 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Np plan to share IPD
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of May-Thurner Syndrome in 1st-degree Relatives of Symptomatic Patients
- ClinicalTrials.gov ID
- NCT05409781
- Acronym / sponsor ID
- MTS / DVS002
- Conditions
- May-Thurner Syndrome
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Decided amongst research group that this project is not feasible
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital of LimerickUniversity, hospital or other
- Study start
- 15 Sep 2025 (estimated)
- Primary completion
- 15 Dec 2025 (estimated)
- Study completion
- 15 Jan 2026 (estimated)
- First posted
- 8 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim is to assess the prevalence of May-Thurner syndrome in 1st-degree relatives of previously identified symptomatic patients.
Detailed description
May-Thurner syndrome (MTS) is a condition characterised by compression of the left common iliac vein by the right common iliac artery and the anterior spine of the 5th lumbar vertebrae. Previously thought to be a rare condition, the prevalence of MTS is thought to be underreported. MTS can lead to significant morbidity in the form of chronic venous insufficiency, venous ulceration, lower limb swelling, venous claudication, deep-vein thrombosis, varicose veins, pelvic congestion syndrome, chronic pelvic pain and chronic post-thrombotic syndrome. It is a known risk factor for development of venous incompetence and varicose veins in adolescents and young adults. Furthermore, it is known to be an a causative factor in the development of "unprovoked" DVT in younger patients, however data on the risk of development of DVT in MTS patients has to date, been unavailable.
The pathogenesis of MTS is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. To date, no studies have previously assessed the prevalence of MTS in relatives of those with the condition.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The pathogenesis of MTS is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. To our knowledge, no studies have previously assessed the prevalence of MTS in relatives of those with the condition.
Key inclusion criteria (1 listed)
- Informed consent, first degree relative with symptomatic May-Thurner syndrome
Key exclusion criteria (1 listed)
- Those who not give informed consent to be contacted or to be scanned.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No InterventionNo Intervention | Other | – |
Primary outcome
Prevalence Assessment
Time frame: 1 year
To assess the prevalence of May-Thurner syndrome amongst 1st-degree relatives of symptomatic individuals referred to the Vascular Department, University Hospital Limerick using duplex ultrasound imaging
1 secondary outcome
Venous Competence Assessment
Time frame: 1 year
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
- Individual participant dataSharing planned: No. Np plan to share IPD
Related trials for May-Thurner Syndrome
Recruiting
Pelvic Vein Quantitative Flow Characterization Using 2D and 4D Flow MRI
May-Thurner Syndrome, Iliac Venous Compression
Not yet recruiting
Embolization of Ovarian Vein and Pelvic Venous Reservoir for Treatment of Secondary Pelvic Congestion Syndrome
Pelvic Congestion Syndrome
RecruitingObservational study
Vascular Lab Resource (VLR) Biorepository
Cardiovascular Diseases, Metabolic Disease
Recruiting
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Deep Vein Thrombosis, Iliac Vein Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of May-Thurner Syndrome, run by University Hospital of Limerick.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence Assessment (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.